STRIVING TOWARDS THE ELIMINATION OF HCV INFECTION
02-03 FEBRUARY 2018
BERLIN, GERMANY

SCIENTIFIC ORGANISING COMMITTEE
Alessio Aghemo, Italy
Jason Grebely, Australia
Francesco Negro, Switzerland

PRELIMINARY* PROGRAMME

DAY 1 – Friday, 2 February 2018

08:00–08:10 Welcome and introductory remarks
Francesco Negro, Switzerland

1. EPIDEMIOLOGY AND PREVENTION

Chairs:
Jason Grebely, Australia
Dagmar Hedrich, Portugal

08:10–08:20 Patient experience
Andi Hüttenmoser, Switzerland

08:20–08:40 Global HCV epidemiology
Angelos Hatzakis, Greece

08:40–09:00 Morbidity and mortality associated with HCV infection
Sharon Hutchinson, United Kingdom

09:00–09:20 Successful interventions for the prevention of HCV infection
Matthew Hickman, United Kingdom

09:20–09:40 Do we still need a vaccine for HCV?
Andrea Cox, United States

09:40–10:10 Discussion

10:10 – 10:30 Coffee break and ePoster session 1

*Subject to change
2. INTERVENTIONS TO IMPROVE LINKAGE OF PATIENTS TO HCV TESTING, CARE, AND TREATMENT

Chairs: Martin Kaberg, Sweden  
        John Dillon, United Kingdom

10:30 – 10:50 Successful strategies to enhance HCV testing, linkage to care, and treatment  
        Jason Grebely, Australia

10:50 – 11:10 Diagnostic tools to improve HCV testing and diagnosis: where do we stand?  
        Jean-Michel Pawlotsky, France

11:10 – 11:30 Scale-up of interventions to improve testing, care and treatment: lessons learned from HIV  
        Philippa Easterbrook, Switzerland

11:30 – 11:50 Engaging marginalized patients in the DAA era  
        Magdalena Harris, United Kingdom

11:50 – 12:20 Discussion

12:20 – 13:30 Lunch break and ePoster sessions 2 and 3

3. TREATMENT OF HCV

Chairs: Alessio Aghemo, Italy  
        Marieta Simonova, Bulgaria

13:30 – 13:50 Management of acute HCV infection  
        Heiner Wedemeyer, Germany

13:50 – 14:10 Management of chronic HCV infection  
        Stefan Zeuzem, Germany

14:10 – 14:30 Direct-acting interferon-free therapies among people who inject drugs  
        Olav Dalgard, Norway

14:30 – 14:50 Managing direct-acting antiviral therapy among people with HIV/HCV co-infection  
        Jürgen Rockstroh, Germany

14:50 – 15:10 Management of treatment failures  
        Massimo Puoti, Italy

15:10 – 15:30 Discussion

15:30 – 16:00 Coffee break and ePoster session 4
4. SETTINGS TO FACILITATE HCV ELIMINATION

Chairs: Angelos Hatzakis, Greece
       Sharon Hutchinson, United Kingdom

16:00 – 16:20 Prisons
       Gregory Dore, Australia
16:20 – 16:40 Drug, alcohol and psychiatry clinics
       Martin Kaberg, Sweden
16:40 – 17:00 General practices, community health centres, and pharmacies
       John Dillon, United Kingdom
17:00 – 17:20 Clinical reality treatment landscape in Eastern Europe
       Marieta Simonova, Bulgaria
17:20 – 17:40 Clinical reality treatment landscape in Western Europe
       Christophe Hézode, France
17:40 – 18:00 Discussion

DAY 2 – Saturday 3 February 2018

5. HOW FAR ARE WE FROM REACHING THE WHO TARGETS OF HCV ELIMINATION?

Chairs: Andrea Cox, United States
       Graham Foster, United Kingdom

08:00 – 08:20 WHO elimination targets and the development of national viral
            hepatitis plans
            Philippa Easterbrook, Switzerland
08:20 – 08:40 What is required from a health systems perspective to achieve HCV
            elimination?
            Jeffrey Lazarus, Denmark
08:40 – 09:00 Cost-effectiveness vs. affordability of HCV treatments
            John Cairns, United Kingdom
09:00 – 09:20 MPP model to scale up access to generic medicines with special
            focus on LMICs
            Ludmila Maistat, Switzerland
09:20 – 09:40 The role of patients’ associations
            Tatjana Reic, United Kingdom
09:40 – 10:30 Coffee break and ePoster sessions 5 and 6

*Subject to change
10:30 – 10:45  The Australian experience  
Gregory Dore, Australia

10:45 – 11:00  The UK experience  
Graham Foster, United Kingdom

11:00 – 11:20  The role of payers  
Ricardo Baptiste Leite, Portugal

11:20 – 11:50  The contribution from the industry  
Fernando Tatsch, United States (10 min)  
Gregg H. Alton, United States (10 min)  
Michael Robertson, United States (10 min)

11:50 – 12:30  Panel discussion (all speakers from session 5 on stage)

12:30 – 14:00  Lunch break and ePoster session 7 and 8

14:00 – 14:30  State-of-the-Art lecture  
Rise and fall of a virus  
Antonio Craxi, Italy

6. IS THE GAME OVER? THE CHALLENGE OF POST-SVR MANAGEMENT

Chairs:  
Massimo Puoti, Italy  
Stefan Zeuzem, Germany

14:30 – 14:50  HCV reinfection following successful DAA therapy  
Patrick Ingiliz, Germany

14:50 – 15:10  Harm reduction and drug user health  
Dagmar Hedrich, Portugal

15:10 – 15:30  Beyond the liver: SVR and extrahepatic manifestations  
Francesco Negro, Switzerland

15:30 – 15:50  Alcohol and SVR: yes, how much, not at all  
Nick Sheron, United Kingdom

15:50 – 16:10  The post-SVR HCC risk: life-long follow-up?  
Alessio Aghemo, Italy

16:10 – 16:30  Discussion

16:30 – 16:40  Concluding remarks

*Subject to change